Literature DB >> 11712096

Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series.

J Delgado1, M Harris, A Tesiorowski, J S Montaner.   

Abstract

Symptomatic lactic acidemia was seen in 5 human immunodeficiency virus-positive patients receiving combination therapy that included stavudine and > or =1 other nucleoside. Peak venous lactic acid levels of 3.1-7.4 mmol/L (normal range, 0.5-2.1 mmol/L) were associated with fatigue and rapid weight loss, whereas withdrawal of antiretrovirals led to normalization of venous lactic acid levels, symptomatic improvement, and weight gain. Resumption of an altered therapeutic regimen, which did not include stavudine but did include other nucleosides in 4 of 5 cases, did not result in recurrence of the syndrome after up to 126 days.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11712096     DOI: 10.1086/323980

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

1.  Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion.

Authors:  Tony Antoniou; Thea Weisdorf; Kevin Gough
Journal:  CMAJ       Date:  2003-01-21       Impact factor: 8.262

2.  Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals.

Authors:  Giovanni Schifitto; Lijuan Deng; Tzu-Min Yeh; Scott R Evans; Thomas Ernst; Jianhui Zhong; David Clifford
Journal:  J Neurovirol       Date:  2010-12-23       Impact factor: 2.643

Review 3.  Adverse effects of antiretroviral therapy for HIV infection.

Authors:  Valentina Montessori; Natasha Press; Marianne Harris; Linda Akagi; Julio S G Montaner
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

4.  Hyperlactatemia in a group of HIV patients living in Yaounde-Cameroon.

Authors:  Corinne Tchoula Mamiafo; Vicky Jocelyne Ama Moor; Jobert Richie N Nansseu; Constant Anatole Pieme; Claude Tayou; Jeanne Ngogang Yonkeu
Journal:  AIDS Res Ther       Date:  2014-01-15       Impact factor: 2.250

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.